Navigation Links
Metamark Genetics Partners with Definiens on Tissue-Based Cancer Diagnostics
Date:6/30/2011

CAMBRIDGE, Mass. and MUNICH, June 30, 2011 /PRNewswire/ -- Metamark Genetics, a privately-held oncology molecular diagnostic company, and Definiens, the leading Health Image Intelligence™ company, today announced a development and commercialization partnership in which Metamark will combine its proprietary multiplex protein detection platform with image analysis technology developed jointly with Definiens to deliver innovative prognostic and predictive assays for early-stage cancers.

"Definiens is a clear world leader in quantitative digital pathology and in the analysis of biomarkers in tissue image data," said Eric Devroe, Ph.D., Vice President of Business & Strategy Development for Metamark. "We see great synergy in combining Definiens' technology and expertise with Metamark's unique understanding of tumor heterogeneity and insight into the molecular drivers regulating tumor formation and aggression. We believe that this partnership will enable us to co-develop and implement unique and important image analysis tools."

Metamark's quantitative diagnostic approach can identify and account for small regions of molecularly aggressive cancer cells within an otherwise indolent tumor. The company is developing a portfolio of prognostic and predictive assays with the ability to address the "heterogeneous" nature of tumors not only between one patient and the next, but also within an individual patient's tumor.

Definiens has made ground-breaking achievements in the field of biomarker development based on its highly robust and scalable image analysis framework that enables scientists and clinicians to rapidly extract comprehensive biomarker and morphology expression profiles and to identify a relevant subset of descriptors by correlating them against patient outcomes.

"Definiens is pleased to partner with Metamark Genetics, and to incorporate our image and data analysis software technology into Metamark's pioneering Oncology diagnostic offerings," said Thomas Colarusso, Vice President of Sales & Operations for Definiens Inc. "The capability to provide detailed readouts from tissue analysis is opening up new gateways for developing diagnostic assays as we enter the age of personalized medicine. We believe the Definiens Developer XD and Tissue Studio software will enable Metamark to classify tumor heterogeneity of multiplexed tissue stains and derive prognostic and predictive assays."

About Metamark Genetics, Inc.

Metamark is a privately held oncology company focused on the development of function-based prognostic assays for early staged cancers. The MetamarkDx™ Prognostic Assays under development are based on Metamark's proprietary Prognosis Determinants™, genes discovered through leading edge cancer research and demonstrated to play a causal role in promoting tumor progression and spread. For further information, please visit the company's website at www.metamarkgenetics.com.

About Definiens

Definiens is a leading Health Image Intelligence™ company that develops software solutions for biomedical image analysis, data mining and clinical decision support. The company's software analyzes images from cell-based assays, whole tissue slides and full body scans and allows users to correlate this information with data derived from other sources, supporting better decisions in research, diagnostics and therapy. By automating analysis workflows and generating new knowledge, Definiens provides pharmaceutical and biotechnology companies, research institutions, clinical service organizations and medical professionals with deeper insights, faster results and better decision support. Harnessing the power of image intelligence, Definiens supports personalized medicine and aims to significantly improve the quality of patients' lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States. Further information is available at www.definiens.com.

Press Contacts:
Metamark Genetics, Inc.
Mark R. Straley
President & CEO
mstraley@metamarkgenetics.com
617-583-1422

Definiens, Inc.
Dr. Martin Baatz
Vice President Marketing
mbaatz@definiens.com


'/>"/>
SOURCE Definiens
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signal Genetics and DiagnoCure Announce a US$13.3M Collaboration for the Commercialization of Previstage™ GCC Colorectal Cancer Staging Test
2. Research 2.0 Updates Coverage of Viral Genetics with Research Report Focused on VG Energy
3. Viral Genetics Updates HIV/AIDS and Drug Resistant Cancer Research Programs
4. Signal Genetics Announces Commercialization Partnership with NeoGenomics Laboratories for Multiple Myeloma Gene Expression Test
5. USP Hospitales of Spain to Offer Interleukin Genetics Heart Health Test Throughout Its Hospital Network
6. Interleukin Genetics and Metagenics Initiate Research Collaboration
7. Technology Collaboration Between New England Biolabs and Sequenom Delivers First Product for Epigenetics
8. LABS, Inc. Announces Alliance with Ambry Genetics to Expand Testing Solutions for the Reproductive Health Industry
9. RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis
10. JS Genetics Develops New Non-Invasive Test, XCAT-TS, to Help Doctors Diagnose Turner Syndrome
11. Viral Genetics Researcher and Advisor Set to Share Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... MOUNTAIN LAKES, N.J. , Sept. 12, 2017  Consumer reviews ... Embrace Hearing as the number one company for hearing ... Oticon™, ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... ... 2017 , ... Lori R. Somekh, founder of the Law Office of ... elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain ... to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
Breaking Medicine News(10 mins):